An estimated 5%–10% of cancer results from an underlying genetic predisposition. For the majority of familial cases, the genes in question remain unknown, suggesting a critical need to identify new cancer predisposition genes. Members of the protein phosphatase 2A (PP2A) family exist as trimeric holoenzymes and are vital negative regulators of multiple oncogenic pathways. PP2A inhibition by somatic mutation, loss of expression, and upregulation of its exogenous inhibitors in tumors has been well described. However, it remains unknown whether germline loss of any PP2A subunits results in a predisposition to cancer in humans. In this study, we identified 9 cancer patients with germline loss-of-function (LOF) variants in PPP2R1B (Aβ), the β isoform of the PP2A scaffold subunit. All 4 patients for whom documentation was available also had a family history of cancer, including multiple indicators of hereditary cancer. Overexpression of these mutant forms of Aβ resulted in truncated proteins that were rapidly turned over. Characterization of an additional missense germline Aβ variant, R233C, which is also recurrently mutated at the somatic level, showed disruption of PP2A catalytic subunit binding, resulting in loss of phosphatase activity. An analysis of Aβ expression among multiple breast cancer cohorts (the most highly represented cancer among the Aβ germline patients) revealed that somatic, heterozygous loss of Aβ was a frequent event in this disease, and decreased Aβ expression correlated with shorter disease-free and overall survival. Furthermore, Aβ levels were significantly lower in multiple histological subtypes of both in situ and malignant breast cancer compared with adjacent normal breast tissue, suggesting that Aβ loss is an early event in breast cancer development. Together, these results highlight a role for Aβ as a predisposition gene in breast cancer and potentially additional cancers.
Sahar Mazhar, Caitlin M. O’Connor, Alexis Harold, Amanda C. Dowdican, Peter J. Ulintz, Erika N. Hanson, Yuping Zhang, Michelle F. Jacobs, Sofia D. Merajver, Mark W. Jackson, Anthony Scott, Anieta M. Sieuwerts, Arul M. Chinnaiyan, Goutham Narla
Usage data is cumulative from April 2025 through March 2026.
| Usage | JCI | PMC |
|---|---|---|
| Text version | 2,110 | 133 |
| 336 | 31 | |
| Figure | 314 | 0 |
| Table | 54 | 0 |
| Supplemental data | 176 | 9 |
| Citation downloads | 82 | 0 |
| Totals | 3,072 | 173 |
| Total Views | 3,245 | |
Usage information is collected from two different sources: this site (JCI) and Pubmed Central (PMC). JCI information (compiled daily) shows human readership based on methods we employ to screen out robotic usage. PMC information (aggregated monthly) is also similarly screened of robotic usage.
Various methods are used to distinguish robotic usage. For example, Google automatically scans articles to add to its search index and identifies itself as robotic; other services might not clearly identify themselves as robotic, or they are new or unknown as robotic. Because this activity can be misinterpreted as human readership, data may be re-processed periodically to reflect an improved understanding of robotic activity. Because of these factors, readers should consider usage information illustrative but subject to change.